Intellia Therapeutics (NTLA) Price & Analysis

Compare

4,689 Followers

NTLA Stock Chart & Stats

$13.05

-$0.56(-4.53%)

At close: Jan 08 4:00 PM EST

$13.05

-$0.56(-4.53%)

Day’s Range― - ―

52-Week Range$5.90 - $28.25

Previous CloseN/A

Volume723.92K

Average Volume (3M)5.20M

Market Cap

$1.51B

Enterprise Value$1.42B

Total Cash (Recent Filing)$511.04M

Total Debt (Recent Filing)$97.97M

Price to Earnings (P/E)―

Beta2.22

Next Earnings

Feb 19, 2026

EPS Estimate

-0.96

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding115,829,926

10 Day Avg. Volume7,516,044

30 Day Avg. Volume5,200,184

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market Cap0.94

Enterprise Value/Revenue24.62

Enterprise Value/Gross Profit-66.11

Enterprise Value/Ebitda-3.10

Forecast

1Y Price Target

$15.53

Price Target Upside19.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering19

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Hereditary Angioedema Program ProgressThe hereditary angioedema candidate achieved full enrollment and benefits from an accelerated review designation after Phase II showed sustained suppression of attacks, supporting a clearer regulatory filing pathway.

Key Opinion Leader EndorsementA key opinion leader with extensive ATTR experience concluded the patient death was likely due to a perforated ulcer rather than drug-induced liver injury, which bolsters clinician confidence in the therapy's safety interpretation.

Market Valuation OpportunityAnalysts contend the market applied an excessive platform-level discount following the safety signal, creating potential upside if trial modifications and resumed enrollment restore investor confidence.

Bears Say

Commercial And Payer RiskPotential for a black box warning combined with payer resistance to high upfront pricing could weaken commercial competitiveness of a TTR gene-editing treatment and pressure future revenue expectations.

Liver-safety OverhangA Hy's Law case and the disclosed patient death leave a material liver-safety overhang that could prompt conservative approval conditions or additional safety trials before broader use is permitted.

Regulatory UncertaintyRegulators may require expanded safety datasets and stricter early monitoring for the cardiac ATTR study, potentially forcing protocol amendments and larger trials that raise development costs and timelines.

Intellia Therapeutics News

Intellia Therapeutics price target raised to $7 from $4 at Baird’

Baird raised the firm’s price target on Intellia Therapeutics (NTLA) to $7 from $4 and keeps a Neutral...

7d ago

NTLA

Intellia Therapeutics price target raised to $25 from $15 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $15...

7d ago

NTLA

Citizens says nex-z return to clinic should add ‘significant value’ to Intellia

Citizens analyst Silvan Tuerkcan notes Intellia announced the FDA lifted the nexiguran ziclumeran hold on the ATTRv-PN side,...

7d ago

NTLA

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors will find a list of the latest earnings reports, analysts updates, and other stock market news in...

8d ago

Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial

Shares in genome editing group Intellia Therapeutics ($NTLA) rocketed higher today after U.S. regulators lifted a freeze on...

8d ago

NTLA

Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study

08:57 EST Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study...

8d ago

NTLA

Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 trial

Intellia Therapeutics (NTLA) announced that the U.S. Food and Drug Administration has removed the clinical hold on the...

8d ago

NTLA

Cathie Wood’s ARK Adds to Intellia Stock (NTLA) — Here’s What Else It Traded This Week

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Thursday, January 15, according to its daily...

19d ago

NTLA

Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics today

20:39 EST Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

19d ago

NTLA

Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Buying Spree?

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics ($NTLA) on Tuesday, extending a...

21d ago

NTLA

Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today

20:01 EST Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

21d ago

NTLA

Cathie Wood Doubles Down on High-Potential Biotech Plays

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Monday, January 12, as revealed in daily fund...

22d ago

TER

TXG

NTLA, PSNL, KMTUY, ILMN: Cathie Wood Buys Early Biotech Stocks, Cuts Stakes in Illumina

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and industrial names on Friday, January 9, 2026....

23d ago

ILMN

NTLA

Intellia Therapeutics price target lowered to $12 from $14 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $14 and keeps a Neutral...

29d ago

NTLA

NTLA FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was $5.90 and its highest was $28.25 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is $1.51B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 15 days.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.005 by $0.085.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.96.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 115,829,926 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.005. Following the earnings report the stock price went down -22.727%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in NTLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Intellia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-21.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (NTLA) Earnings & Revenues

Historic Earnings Reports

NTLA Revenue Breakdown

100.00% Collaboration revenue

NTLA Stock 12 Month Forecast

Average Price Target

$15.53

▲(19.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","10":"$10","16":"$16","22":"$22","28":"$28"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10,16,22,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,10.375384615384615,11.760769230769231,13.146153846153846,14.53153846153846,15.916923076923077,17.302307692307693,18.68769230769231,20.073076923076922,21.458461538461535,22.84384615384615,24.229230769230767,25.614615384615384,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,9.493076923076924,9.996153846153845,10.499230769230769,11.002307692307692,11.505384615384616,12.008461538461539,12.51153846153846,13.014615384615384,13.517692307692307,14.020769230769229,14.523846153846153,15.026923076923076,{"y":15.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.99,8.683076923076923,8.376153846153846,8.069230769230769,7.762307692307692,7.455384615384615,7.148461538461539,6.841538461538462,6.5346153846153845,6.227692307692307,5.92076923076923,5.613846153846154,5.306923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 45, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >